David Epstein joined Seagen as Chief Executive Officer and a member of the Board of Directors in 2022, bringing more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Prior to Seagen, he was executive partner at Flagship Pioneering. From 2010 to mid-2016 he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. David holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business. He serves as a member of the board of directors for OPY Acquisition Corp. I and Senti Biosciences, Inc. w/ Special Guest Host: Brian Fiske - Co-Founder & CSO @ Mythic Therapeutics Brian Fiske co-founded Mythic in 2017 & currently serves as Mythic’s Chief Scientific Officer. Prior to Mythic, he was a co-founder and Chief Technology Officer at Ohana Biosciences and a Senior Associate at Flagship Ventures, where he also co-founded KSQ Therapeutics. During his time at Flagship, Brian successfully led R&D teams to key milestones, recruited 25+ FTEs across all levels of seniority, and raised $34M across multiple rounds of financing. In 2016, he was nationally recognized for healthcare entrepreneurship by Forbes 30 under 30. Prior to Flagship, Brian completed his PhD in biology in Matt Vander Heiden’s lab at MIT where he published over 10 papers in the field of cancer metabolism. He also worked closely with Agios Pharmaceuticals (NASDAQ: AGIO) on their cancer metabolism programs, which have since translated into four clinical programs that include two approved drugs. He holds an AB summa cum laude in Biochemical Sciences with a secondary field in Economics from Harvard University. Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors. Thank you for listening! BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health. Music: Danger Storm by Kevin MacLeod (link & license)